Clinical trials: Esomeprazole
Barrett's Esophagus
An Open Label pH Comparison of Esomeprazole and Lansoprazole in Barrett's Esophagus Patients
The purpose of the study is to compare the treatment of esomeprazole 40 mg once daily and lansoprazole 30 mg once daily in controlling intragastric pH in Barrett's Esophagus patients
- Trial name
- NCT00352261
- Testing
- Esomeprazole, Lansoprazole
- Where
- 12 sites in United States
- Volunteers
- 80 people
- Sponsor
- AstraZeneca
Healthy Volunteers With Ileostomy
A Study Evaluating the Effect of Esomeprazole on SYN-004 Degradation of Ceftriaxone In Adults With an Ileostomy
A Phase 1b/2a, Multi-Center, Open-Label, 2-Period, Fixed-Sequence Study Evaluating the Effect of Esomeprazole on SYN-004 Degradation of Ceftriaxone In Healthy Adult Subjects with a Functioning Ileostomy
- Trial name
- NCT02473640
- Testing
- SYN-004, Esomeprazole, Ceftriaxone
- Where
- 2 sites in Canada
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Theriva Biologics, Inc.
Gastroesophageal Reflux Disease
Drug Interaction Study Between AZD3355 and Nexium
The purpose of the study is to evaluate if AZD3355 and Nexium interact with each other or not, i.e. show the same or altered plasma concentration profiles when co-administered compared to administered alone.
- Trial name
- NCT00684190
- Testing
- AZD3355, Esomeprazole
- Where
- Sweden
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Volunteer
A Study Investigating the Effect of Food and Esomeprazole on the Single Oral Dose Pharmacokinetics of Alectinib (RO5424802) in Healthy Volunteers.
This two-group study will investigate the effect of food (Group 1) and esomeprazole (Group 2) on the single oral dose pharmacokinetics of alectinib in healthy volunteers.
- Trial name
- NCT02023125
- Testing
- Alectinib, Esomeprazole, High Fat and Calorie Meal
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
GERD
Esomeprazole for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs
This study is a randomised, double-blind, parallel-group and placebo controlled study comparing the efficacy of esomeprazole 40 mg orally qd vs. placebo and esomeprazole 20 mg orally qd vs.
- Trial name
- NCT00241540
- Testing
- Esomeprazole
- Where
- 119 sites in United States, Belgium and 4 more
- Volunteers
- 808 people
- Sponsor
- AstraZeneca
Reflux Esophagitis
Reflux Esophagitis Phase III Study (Initial Treatment)
This study is to evaluate the efficacy of esomeprazole 20 mg once daily and 40 mg once daily for 8 weeks on healing of Reflux Esophagitis in patients with reflux esophagitis in comparison with omeprazole 20 mg once daily by…
- Trial name
- NCT00633932
- Testing
- Esomeprazole, Omeprazole
- Where
- 41 sites in Japan
- Volunteers
- 602 people
- Sponsor
- AstraZeneca
Healthy Subjects
Drug-drug Interaction Study of XZP-3621 Tablet
This is an open-label, single center, 2 period, one sequence study to investigate the potential drug drug interaction between itraconazole or rifampin or esomeprazole and XZP-3621 tablet.
- Trial name
- NCT05586568
- Testing
- XZP-3621 tablet and itraconazole oral liquid (for Arm1), XZP-3621 tablet and Rifampicin capsules (For Arm 2), XZP-3621 tablet and esomeprazole tablet (For Arm3)
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
Stress Ulcer Prophylaxis
Stress Ulcer Prophylaxis of Intravenous Esomeprazole in Chinese Seriously Ill Patients
The efficacy of esomeprazole will be compared versus cimetidine (a drug that previously demonstrated prevention of bleeding events) during treatment period in proportion of patients for the prevention of upper GI bleeding.
- Trial name
- SUP (NCT02157376)
- Testing
- Esomeprazole, Cimetidine
- Where
- 15 sites in China
- Volunteers
- 343 people
- Sponsor
- AstraZeneca
Gastric Ulcer, Duodenal Ulcer, Anastomotic Ulcer, Reflux Oesophagitis,"Non-erosive Reflux Disease, Zollinger-Ellison Syndrome
Nexium Capsules Clinical Experience Investigation
The purpose of this study is to confirm the safety profile / factors which impact safety and efficacy of Nexium capsules in daily clinical usage for the patients who have been prescribed Nexium for "gastric ulcer", "duodenal…
- Trial name
- NCT01434485
- Where
- 47 sites in Japan
- Volunteers
- 3,691 people
- Sponsor
- AstraZeneca
Healthy Volunteers
A Study of Interaction of Zasocitinib (TAK-279) With Other Medicines in Healthy Adults
The main aim of this study is to find out how zasocitinib (TAK-279) interacts with other medicines taken by mouth (orally). This will be examined by how the body processes medicines, which is called pharmacokinetics or PK.
- Trial name
- NCT06793943
- Testing
- Zasocitinib, COC, Metformin
- Where
- United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Takeda
Heartburn
Esomeprazole And Symptomatic Response In Patients With Or Without An Elevated Risk For Non-Steroidal Anti-Inflammatory Drug (NSAID)-Associated GI Damage
The purpose of this study is to compare the treatment effect in patients with upper gastro-intestinal complaints with an elevated risk for NSAID-associated GI-damage to those without an elevated risk for NSAID-associated damage…
- Trial name
- Synchronise (NCT00524329)
- Volunteers
- 1,220 people
- Sponsor
- AstraZeneca
Bioequivalence Study
Study to Assess the Bioequivalence Between D961S and Esomeprazole/Buffered Acetylsalicylic Acid (ASA) in Japanese Healthy Male Subjects
The purpose of this study is to assess bioequivalence between D961S and esomeprazole/buffered ASA, safety, tolerability of esomeprazole in combination with ASA and pharmacokinetics (PK) of D961S, esomeprazole and buffered ASA…
- Trial name
- NCT01494402
- Testing
- D961S, Esomeprazole, Buffered acetylsalicylic acid
- Where
- Japan
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
Comparison Study of a New Combination of 2 Marketed Medications (Esomeprazole and Naprosyn) Versus Naprosyn Alone
The purpose of this study is to determine whether the absorption of naproxen from the PN 400 combination (Naprosyn and Esomeprazole) tablets is similar to that from the naproxen tablets (Naprosyn®), which are currently sold in…
- Trial name
- NCT00992381
- Testing
- PN400, Naprosyn
- Where
- Australia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Arthritis
Study Evaluating the Bioavailability of Naproxen 500 mg in Three Formulations
We will evaluate the bioavailability of naproxen 500 mg administered as three dfferent formulations.
- Trial name
- NCT00665743
- Testing
- PN400, naproxen
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- POZEN
Anti-Ulcer Agents
Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of JP-1366 Oral Administration in Healthy Male Subjects
Clinical trial to investigate the safety, tolerability and pharmacokinetics and pharmacodynamics of JP-1366 oral administration in healthy male subjects
- Trial name
- NCT03383042
- Testing
- Cohort 1 (JP-1366 A mg), Cohort 2 (JP-1366 B mg), Cohort 3 (JP-1366 C mg)
- Where
- South Korea
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
GERD Without Erosive Esophagitis
A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients Without Erosive Esophagitis.
The primary objective is to compare the efficacy between three doses of AZD0865 (25, 50 and 75 mg). The secondary objectives are to compare the efficacy between the three doses of AZD0865 and esomeprazole 20 mg and to evaluate…
- Trial name
- NCT00206284
- Testing
- AZD0865
- Where
- 202 sites in United States, Canada and 8 more
- Volunteers
- 1,400 people
- Sponsor
- AstraZeneca
Solid Tumors, Lymphoma
Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib
The purpose of this study is to assess the drug-drug interaction (DDI) of either esomeprazole or rifampin on the single-dose PK of alisertib, and to complete an intensive QT study of single and multiple-dose alisertib.
- Trial name
- NCT01844583
- Testing
- Alisertib, Esomeprazole, Rifampin
- Where
- 7 sites in United States
- Volunteers
- 55 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Gastric Ulcer, Duodenal Ulcer
Nexium Capsules Helicobacter Pylori Specific Clinical Experience Investigation
The purpose of this study is to confirm the safety profile / factors which impact safety and efficacy in patients given triple therapy for Helicobacter pylori eradication with Nexium + amoxicillin (AMPC) + clarithromycin (CAM)…
- Conditions
- Gastric Ulcer, Duodenal Ulcer, Gastric Mucosa-associated Lymphoid Tissue (MALT), Lymphoma Idiopathic Thrombocytopenic Purpura
- Trial name
- NCT01435525
- Where
- 36 sites in Japan
- Volunteers
- 369 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease
Study Comparing Esomeprazole Associated With Sodium Bicarbonate From Eurofarma and Esomeprazole in Treatment of Gastroesophageal Reflux Disease ESOBIC
A phase III, randomized, open-label, superiority study comparing the incremental product esomeprazole associated with sodium bicarbonate made by Eurofarma and Nexium® in the treatment of gastroesophageal reflux disease.
- Trial name
- NCT01471925
- Testing
- Nexium®, Esomeprazol (40mg) + Sodium Bicarbonate (721mg)
- Where
- 6 sites in Brazil
- Sponsor
- Eurofarma Laboratorios S.A.
Gastro-oesophageal Reflux
A Study to Compare the Number of Patients With Gastro-Oesophageal Reflux Disease (GORD) Achieving Heartburn and Regurgitation Symptom Resolution After Treatment With Either Rabeprazole Sodium 20mg, Esomeprazole 20mg or Esomeprazole 40mg
The primary objective of this study is to compare, the number of patients with heartburn and regurgitation symptom resolution after treatment with either rabeprazole 20 mg, esomeprazole 20 mg or esomeprazole 40 mg.
- Trial name
- NCT00464308
- Testing
- Esomeprazole, Rabeprazole
- Where
- 25 sites in Australia
- Volunteers
- 1,392 people
- Sponsor
- Janssen-Cilag Pty Ltd